Skip to main content
Premium Trial:

Request an Annual Quote

Nuclea Acquires Tissue Microarray IP

NEW YORK (GenomeWeb News) – Nuclea Biotechnologies today announced the acquisition of a portfolio of six patents and applications related to tissue microarrays for an undisclosed amount.

Nuclea acquired the IP from Laurus Master Fund, a division of Laurus Capital Management. Clinomics Biosciences previously owned the IP and assigned it to Laurus, but since then, the patents have not been maintained, Nuclea said, adding that it plans to petition the US Patent and Trademark Office immediately to revive them.

Nuclea President and CEO Patric Muraca is the inventor of all the technologies in the patent portfolio purchased from Laurus. He was previously the president and COO of Clinomics.

"We believe these patents will allow Nuclea to expand our product offering and drive significant licensing revenue for the company," Muraca said in a statement. "The tissue microarray technologies contained in this portfolio are very useful in specimen analysis, and we are eager to integrate them into our research."

The Scan

Shape of Them All

According to BBC News, researchers have developed a protein structure database that includes much of the human proteome.

For Flu and More

The Wall Street Journal reports that several vaccine developers are working on mRNA-based vaccines for influenza.

To Boost Women

China's Ministry of Science and Technology aims to boost the number of female researchers through a new policy, reports the South China Morning Post.

Science Papers Describe Approach to Predict Chemotherapeutic Response, Role of Transcriptional Noise

In Science this week: neural network to predict chemotherapeutic response in cancer patients, and more.